Free Trial

Geode Capital Management LLC Boosts Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Allogene Therapeutics logo with Medical background

Geode Capital Management LLC grew its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 14.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,227,104 shares of the company's stock after buying an additional 407,070 shares during the period. Geode Capital Management LLC owned approximately 1.54% of Allogene Therapeutics worth $9,037,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bank of New York Mellon Corp grew its position in Allogene Therapeutics by 20.6% in the second quarter. Bank of New York Mellon Corp now owns 362,364 shares of the company's stock worth $844,000 after acquiring an additional 61,811 shares in the last quarter. Rothschild Investment LLC purchased a new position in shares of Allogene Therapeutics in the 2nd quarter worth approximately $52,000. Rhumbline Advisers increased its position in shares of Allogene Therapeutics by 8.2% during the 2nd quarter. Rhumbline Advisers now owns 164,508 shares of the company's stock valued at $383,000 after purchasing an additional 12,473 shares during the last quarter. TD Asset Management Inc raised its holdings in Allogene Therapeutics by 82.7% during the 2nd quarter. TD Asset Management Inc now owns 799,340 shares of the company's stock valued at $1,862,000 after buying an additional 361,904 shares during the period. Finally, Arizona State Retirement System raised its holdings in Allogene Therapeutics by 36.1% during the 2nd quarter. Arizona State Retirement System now owns 40,915 shares of the company's stock valued at $95,000 after buying an additional 10,855 shares during the period. 83.63% of the stock is owned by hedge funds and other institutional investors.

Allogene Therapeutics Trading Up 3.3 %

Shares of NASDAQ ALLO traded up $0.07 during trading hours on Thursday, reaching $2.20. The stock had a trading volume of 3,451,958 shares, compared to its average volume of 2,492,003. The business's fifty day moving average price is $2.37 and its two-hundred day moving average price is $2.54. The firm has a market cap of $461.28 million, a price-to-earnings ratio of -1.41 and a beta of 0.83. Allogene Therapeutics, Inc. has a 52-week low of $1.78 and a 52-week high of $5.78.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ALLO. William Blair reiterated an "outperform" rating on shares of Allogene Therapeutics in a research report on Thursday, November 14th. HC Wainwright reissued a "buy" rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a research report on Friday, November 8th. Finally, Piper Sandler dropped their target price on Allogene Therapeutics from $11.00 to $9.00 and set an "overweight" rating for the company in a research report on Thursday, November 14th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $9.73.

Read Our Latest Analysis on ALLO

About Allogene Therapeutics

(Free Report)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).

See Also

Institutional Ownership by Quarter for Allogene Therapeutics (NASDAQ:ALLO)

Should You Invest $1,000 in Allogene Therapeutics Right Now?

Before you consider Allogene Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allogene Therapeutics wasn't on the list.

While Allogene Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Oracle’s Cloud Shift Pays Off: Will Momentum Continue?

Oracle’s Cloud Shift Pays Off: Will Momentum Continue?

Analysts boosting their targets. Find out how Oracle’s cloud push is reshaping its business and driving new growth opportunities.

Recent Videos

Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025
Investing in Quantum Computing: Is Rigetti the Stock to Watch?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines